Survival: 9.0 months     Toxicity Grade: 2     Treatments: Immunotherapy     Drugs: Proleukin

Country: United Kingdom     City/State/Province: London     Hospital: St. Bartholomew’s Hospital     Journal: Link     Date: 1/2001

Description:

Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy. Treatment: The treatment consisted of the administration of human recombinant Interleukin-2. Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains. Results: Overall median survival was 9 months from the date of first treatment. Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin). Correspondence: R.M. Rudd, MD